Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: ribupatide, KAI-9531, KAI-9531-T
HRS9531 is a clinical-stage dual GLP-1/GIP receptor agonist peptide investigated in injectable and oral formulations. Published preclinical and first-in-human data describe in-vitro activation of both GLP-1 and GIP receptor pathways, subcutaneous bioavailability in animal models, and pharmacodynamic effects including reduced body weight, food intake, and fasting plasma glucose in studied models and participants.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Phase 1 injectable research included single ascending doses of 0.1, 0.3, 0.9, 2.7, 5.4, and 8.1 mg and multiple ascending dose regimens of 0.9, 2.7, and 5.4 mg, including a 2.7/2.7/4.0/5.4 mg escalation sequence, administered subcutaneously once weekly for four weeks. A phase 2 obesity study reported once-weekly subcutaneous doses of 1.0, 3.0, 4.5, and 6.0 mg for 24 weeks. Oral tablet phase 1 research evaluated single doses of 3, 10, 25, or 50 mg and daily multiple-dose regimens of 10 mg or 10 mg followed by 25 mg. These are published study regimens and not treatment recommendations.
Supplementary research context only. Not medical advice or a treatment recommendation.
HRS9531; ribupatide; KAI-9531; KAI-9531-T; PubMed PMID 42764407; DOI 10.1111/dom.71218; ClinicalTrials.gov NCT05152277
The compound is investigational and has been studied in clinical trials involving healthy participants and people with obesity or type 2 diabetes. Publicly available authoritative sources do not provide a complete primary amino-acid sequence, molecular formula, CAS Registry Number, or validated physicochemical profile.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention HRS9531 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.